title: [Venlafaxine and its discontinuation syndrome].
authors.forename: L
authors.initials: L
authors.lastname: Sierra Santos
authors.forename: Y
authors.initials: Y
authors.lastname: Raigal Martín
authors.forename: A
authors.initials: A
authors.lastname: Ortega García
authors.forename: C
authors.initials: C
authors.lastname: Barriochoa Martínez de Pisón
authors.forename: G
authors.initials: G
authors.lastname: Aparicio Jabalquinto
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001288:Attention / Q000187:drug effects*; D003511:Cyclohexanols / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008569:Memory Disorders / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis*; D000069470:Venlafaxine Hydrochloride; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride